{"id":"W4323353350","doi":"10.1016/j.clml.2023.03.002","title":"Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Loxo Oncology; Pharmacyclics; Kite Pharma; Genentech; National Cancer Institute; Gilead Sciences; Servier; Alexion Pharmaceuticals; Apellis Pharmaceuticals; BeiGene; Pfizer; Incyte; Innovent Biologics; Adaptive Biotechnologies; Sierra Oncology; CTI Biopharma; bluebird bio; TG Therapeutics; Regeneron Pharmaceuticals; Sanofi; Amgen; AstraZeneca; Cidara Therapeutics; MorphoSys; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Vaccination; Seroconversion; Lymphoma; Immunology; Multiple myeloma; Antibody; Cancer; Chimeric antigen receptor; Immune system; Immunotherapy; Virology; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004631198,0.0002567216,0.0005588031,0.0003242744,0.0003625911,0.0005259367,0.0002490107,0.0007043667,0.001824833],"category_scores_gemma":[0.002279836,0.0001611158,0.0004830548,0.0003707453,0.000239872,0.0004810429,0.000288063,0.0007767992,0.0003105797],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005482665,"about_ca_system_score_gemma":0.0002974342,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001743339,"about_ca_topic_score_gemma":0.002342059,"domain_scores_codex":[0.9995193,0.0001301398,0.00003625059,0.0000869949,0.00005682014,0.0001704634],"domain_scores_gemma":[0.9990257,0.000392033,0.0002034819,0.00003402678,0.00008143286,0.0002632165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009157254,0.0004995675,0.972177,0.00005533837,0.0001611748,0.0007184517,0.000216316,0.0002693041,0.00217108,0.00003374332,0.0006043396,0.01393635],"study_design_scores_gemma":[0.0001873825,0.003688346,0.993258,0.00001707715,0.0001217001,0.0007786778,0.0002814065,0.000479282,0.0003316197,0.00004323768,0.0008021612,0.0000110004],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979239,0.0005518837,0.00003438742,0.000153095,0.00002862389,0.00001515354,0.000143998,0.000005692006,0.001143228],"genre_scores_gemma":[0.9992918,0.00007553738,0.00001912046,0.0001329967,0.00003043691,0.00001064138,0.0001851945,0.000001174525,0.0002530136],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001824833,"threshold_uncertainty_score":0.006104648,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03695353903935361,"score_gpt":0.3572703254441805,"score_spread":0.3203167864048269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}